After Recognify Life Sciences Inc.’s phase IIb failure in treating the cognitive impairment in those with schizophrenia, the indication is no closer to a U.S. FDA approved therapy. The ...

Two-Phase Study Leads to Monteloeder's Newest Nootropic for Cognitive Performance Provided by PR Newswire Feb 25, 2025 4:00am ...

“We are excited to advance MT1988 into Phase II trials, where we aim to demonstrate clinical proof of concept in improving cognitive function in patients living with schizophrenia and related ...

Cognition Therapeutics Reports Improvement In Cognitive Outcomes In Phase 2 SHINE Study In AD. July 29, 2024 — 08:37 am EDT Written by RTTNews.com for RTTNews -> ...

The ERUDITE study was the second Phase 2 trial for luvadaxistat. It failed to replicate the cognitive endpoints data seen in the earlier INTERACT™ study, due in part to the large variability ...

Ram Mukunda, CEO of IGC Pharma, commented, "The cognitive improvements observed in our interim results align with preclinical evidence of IGC-AD1's active pharmaceutical ingredients' impact on ...

Co announces positive cognitive function results from its Phase 1b multiple ascending dose clinical trial of PRX-07034, the co's internally-discovered, novel 5-HT6 antagonist being developed for ...

“We are excited to advance MT1988 into Phase II trials, where we aim to demonstrate clinical proof of concept in improving cognitive function in patients living with schizophrenia and related ...